Endonovo Therapeutics, Inc.
ENDV· OTC
ENDVEndonovo Therapeutics, Inc.
Filed Aug 19, 2013 · 10-Q · 50 days after period end · 0001469709-13-000504
| Metric | Q2 2013 | Q2 2012 |
|---|---|---|
| Revenue | $0.00 | $8.09K |
| Net Income | -$639.99K | -$430.61K |
| EPS Diluted | -$0.01 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
ended Jun 30, 2013 · filed Aug 19, 2013 · 50 d after period end
